Midsummer is considered prime beach season, but investors know that, more importantly, it's second-quarter earnings season.

With that in mind, this episode of The Motley Fool's Market Checkup is dedicated to the world's largest health-care conglomerate, Johnson & Johnson (NYSE:JNJ). Watch and find out how the second-quarter results of  Big Pharma stocks stack up, and what challenges and opportunities lie ahead for for each of its business segments.

In this video, health-care analysts David Williamson and Max Macaluso drill down on Johnson and Johnson's fastest-growing division: pharmaceuticals. Watch and find out why, after a few sleepy years, this division is showing robust growth on key product launches, including whether the company's strong performance can continue into the future.

Follow David on Twitter: @MotleyDavid.

David Williamson  owns shares of Johnson & Johnson. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.